Clinical Trials Logo

Safety and Tolerability clinical trials

View clinical trials related to Safety and Tolerability.

Filter by:

NCT ID: NCT02029482 Completed - Clinical trials for Safety and Tolerability

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This was a single-center, randomized, double-blind, placebo-controlled, up-titration Phase 1 study. Sixteen subjects in two groups (at least 40% of subjects of either male or female sex), with 12 subjects in the active treatment group with an up-titration scheme from 10 to 100 mg, and 4 subjects in the placebo treatment group. Subjects were administered ascending doses of ACT-128800/placebo once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.

NCT ID: NCT01952548 Completed - Clinical trials for Safety and Tolerability

Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers

Start date: May 2013
Phase: Phase 1
Study type: Interventional

This study will test single doses of the study drug in increasing amounts to see if it is safe.

NCT ID: NCT01907867 Completed - Clinical trials for Safety and Tolerability

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

Start date: January 2012
Phase: Phase 1
Study type: Interventional

This study investigates the safety, tolerability, and PK profile of finafloxacin as a novel fluoroquinolone and a potential therapeutic agent for lower respiratory infections such as bacterial pneumonia. A comparison of the PK profile of finafloxacin in plasma and lung ELF using different bronchoscopic ELF sampling techniques (BMS and BAL) is conducted.

NCT ID: NCT01895946 Completed - Clinical trials for Safety and Tolerability,

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability

OAK
Start date: December 2013
Phase: Phase 1
Study type: Interventional

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability

NCT ID: NCT01692262 Completed - Pharmacokinetics, Clinical Trials

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

PYRUS
Start date: November 2012
Phase: Phase 1
Study type: Interventional

To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy, in patients with metastatic Castrate-Resistant Prostate Cancer. AZD5363 will be investigated in patients who have progressed after chemotherapy (Part A) and in patients who have progressed before receiving chemotherapy (Part B). Recruitment into Part A, Group 1 has been suspended. A new design for this group is currently being evaluated. Part A, group 2 patients (progressed after 1 or more 2nd generational anti-hormonal therapies) will receive AZD5363 480mg bid intermittently (4 days on/3days off). Part B will only start if there is evidence of anti-tumour activity along with AZD5363 having an acceptable safety profile in Part A. Part B will be conducted in pre-chemotherapy patients on a dose and schedule selected from Part A.